Aptevo Therapeutics, Inc.(NASDAQ : APVO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.16%||69.56||1.0%||$505.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.18%||635.16||2.7%||$472.48m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.31%||203.81||1.9%||$464.56m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-4.21%||4.10||0.7%||$286.61m|
|EXAS||EXACT Sciences Corp.||-4.94%||76.59||18.0%||$140.15m|
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.